Location History:
- Mewbury Park, CA (US) (2021)
- Newbury Park, CA (US) (2016 - 2024)
Company Filing History:
Years Active: 2016-2025
Title: Innovator Chung-Jr Huang: Advancements in Recombinant Protein Production
Introduction
Chung-Jr Huang, based in Newbury Park, CA, is an accomplished inventor with a significant contribution to the field of biotechnology. He holds an impressive portfolio of 10 patents, primarily focusing on enhancing recombinant protein production processes. His innovative work is set to pave the way for more efficient biological manufacturing techniques.
Latest Patents
One of Chung-Jr Huang's notable patents includes methods for increasing mannose content of recombinant proteins. This invention details strategies for enhancing the high mannose glycoform content of recombinant proteins during mammalian cell culture. By manipulating the mannose to total hexose ratio within the cell culture media formulation, the methods aim to improve the quality and efficacy of recombinant proteins produced.
Career Highlights
Throughout his career, Chung-Jr Huang has worked with leading organizations such as Amgen Inc. and Cornell University. His experience in these prominent institutions has provided him with a robust foundation in biotechnology research and development, contributing to his success as an inventor.
Collaborations
Chung-Jr Huang has collaborated with distinguished colleagues in his field, including Xiaoming Yang and David Putnam. These partnerships have enriched his research endeavors, fostering innovative approaches to complex challenges in recombinant protein production.
Conclusion
With his impressive array of patents and his commitment to advancing biotechnological methods, Chung-Jr Huang has established himself as a noteworthy inventor. His work not only contributes to scientific knowledge but also enhances industrial applications, ultimately benefiting the healthcare sector and beyond. As he continues to innovate, the impact of his contributions will likely resonate throughout the field of biotechnology for years to come.